Related Experiment Videos
Therapeutic plasmapheresis for post-operative hepatic failure
1First Department of Surgery, Shiga University of Medical Science, Japan.
Progress in Clinical and Biological Research
|January 1, 1990
Summary
Post-surgical hepatic failure (PHF) treatment is challenging due to complications. Nafamostat Mesilate (FUT-175) shows promise as a safe and effective anticoagulant for PHF patients with bleeding.
Area of Science:
- Hepatology
- Pharmacology
- Critical Care Medicine
Background:
- Post-surgical hepatic failure (PHF) presents a poor prognosis.
- Complications include hemostatic disorders, surgical stress, and fresh wounds.
- Current treatments are limited, with extracorporeal devices requiring anticoagulation.
Purpose of the Study:
- To evaluate Nafamostat Mesilate (FUT-175) as an anticoagulant in patients with PHF and bleeding.
- To assess the safety and efficacy of FUT-175 in this patient population.
Main Methods:
- Nafamostat Mesilate (FUT-175), a serine protease inhibitor, was administered to 15 patients with PHF and bleeding.
- FUT-175 is a short-acting anticoagulant whose degradation is independent of liver function.
Main Results:
- No adverse side effects were observed in the treated patients.
- No aggravation of bleeding occurred during FUT-175 administration.
- FUT-175 demonstrated a favorable safety profile in this cohort.
Conclusions:
- Nafamostat Mesilate (FUT-175) is a potential ideal anticoagulant for managing bleeding in post-surgical hepatic failure.
- Its properties make it suitable for patients with impaired liver function.
- Further research is warranted to confirm its efficacy in larger trials.